

Molecular diagnosis and antimicrobial resistance pattern of *Shigella* spp. isolated from patients with acute diarrhea in Tehran, Iran

Fereshteh Jafari, Mohammad Hamidian, Siavoshe Salmanzadeh-Ahrabi, Mehdi Bolfion, Pedram Kharaziha, Mohammad Yaghobi, Mohammad Reza Zali

Research Center for Gastroenterology and Liver Diseases, Shahid Beheshti University M.C., Tehran, Iran

ABSTRACT

Aim: To evaluate antimicrobial resistance pattern of *Shigella* spp. isolated from patients with acute diarrhea in Tehran, Iran.

Background: Infectious diarrheal diseases caused by *Shigella* spp. are significant health concern world wide. They are responsible for considerable morbidity and mortality especially in developing countries.

Patients and methods: A total of 1120 fecal samples from patients with acute diarrhea from May 2003 to May 2005 were investigated to evaluate antimicrobial susceptibility patterns of predominant isolates from different hospitals in Tehran, Iran. Identification of isolates was carried out according to standard methods.

Results: Among isolated enteropathogens, *Shigella* spp. were found in 14%. *Shigella sonnei* was commonest (56.1%) followed by *Shigella flexneri*, *boydii* and *dysenteriae* that were found in 30.6%, 8.3% and 5.1% of isolates, respectively. Of all isolates, 66.3% were detected in patients less than 5 years old. Resistance pattern was as follow: tetracycline 95.5%, ampicillin 51.5% and trimethoprim-sulfamethoxazole 91.7%. None of the isolates were resistant to ciprofloxacin, ceftriaxone and ceftazidime. An interesting finding in our study was a high degree of multidrug resistance to 3 and more antibiotics among isolates 91%.

Conclusion: In conclusion, *Shigella* species isolated from acute diarrhea in Iran have a high degree of resistance to commonly used antibiotics. The emergence of multidrug-resistance demands continues monitoring of susceptibility pattern of *Shigella* isolates. The changing of resistance pattern to common antibiotics in Iran indicates that designing a monitoring system for detection of antimicrobial resistance and guidelines for the appropriate use of antibiotics are urgently needed.

Keywords: *Shigella*, Antimicrobial resistance, Diarrhea, Iran.

(Gastroenterology and Hepatology from bed to bench 2008;1(1):11-17).

INTRODUCTION

Infectious diarrheal diseases caused by *Shigella* spp. are significant health concern world wide. They are responsible for considerable morbidity and mortality especially in developing countries (1, 2). It has been estimated that annually 1.1 millions

of all deaths are attributable to shigellosis through the world. The diarrheal diseases in children are responsible for 25% of all deaths (1). The annually number of shigellosis is approximately 164.7 cases world wide while 163.2 millions of the cases are in developing countries (3). *Shigella* is the most important bacterial causes of diarrhea in children less than 5 years old. *Shigella* is divided to four species, classified on the basis of biochemical and

Received: 3 August 2007 Accepted: 7 September 2007

Reprint or Correspondence: Fereshteh Jafari.

Research Center for Gastroenterology and Liver Diseases, 7th floor, Taleghani hospital, Evin, Tehran, Iran.

E-mail: f_jaafari580@yahoo.com

serological differences including *S. dysenteriae* (Group A), *S. flexneri* (Group B), *S. boydii* (Group C), and *S. sonnei* (Group D) (3,4).

The predominant serogroup of *Shigella* is associated with the level of socioeconomic development. *Shigella flexneri* is the main serogroup found in developing countries (median 60% isolates) with *sonnei* being the next most common (median 15%). *Shigella dysenteriae*, which is found most often in south Asia, and sub-Saharan Africa, and *Shigella boydii* occur with equal frequency (median 6%) (5). *S. boydii* and *S. sonnei* are associated with mild short illness whereas infections caused by *S. flexneri* are more severe and last longer. Finally, *S. dysenteriae* causes the most severe illnesses associated with a high mortality rate (6).

Despite other enteric infections, shigellosis is one of acute diarrheal diseases for which antimicrobial therapy is prescribed (7). Over the past decades, *Shigella* spp. have shown a pattern of steadily increasing resistance to antibiotics and, strains of *Shigella* have progressively become resistant to most of the widely used antimicrobial agents and even newer antibiotics (8).

In the developing world, where the rate of diarrheal diseases is highest and indiscriminate use of antimicrobial agents is common, antimicrobial resistance in enteric pathogens is of utmost importance (7). Therefore, determination of antibiotic susceptibility of *Shigella* strains will be useful to administer the best antibiotic. The recovery rates of *Shigella* spp. are usually difficult to obtain in that these are very fastidious organisms and need special conditions to growth. These conditions usually take 48 to 72 h to provide (9). The present study was designed to investigate the antimicrobial resistance pattern of *Shigella* spp. based on biochemical, microbiological, and molecular diagnostic techniques in a group of Iranian patients with acute diarrhea.

PATIENTS and METHODS

Sample collection and bacteriologic isolation:

Sampling was performed during May 2003 to May 2005 from 6 different hospitals in Tehran. Fecal samples from patients with acute diarrhea were transported to the laboratory of National Research Department of Foodborne Diseases in Research Center for Gastroenterology and Liver diseases (RCGLD) in Tehran, in Cary-Blair and PBS transport media on ice packs and processed within the first hours following. Samples were cultured directly on MacConkey agar, Xylose-Lysine, De carboxylate agar and Salmonella-Shigella agar and incubated at 37°C over night.

Serological typing:

Colonies, morphologically resembling *Shigella* species, were further identified by biochemical reactions according to the standard methods (10) and confirmed by slide agglutination test using commercially available antisera from Mast Group Ltd. (MAST House, Derby Road, Bootle, Merseyside, L201EA, UK).

PCR Amplification:

DNAs were extracted from the organisms as described above (11). *IpaH* gene on the chromosome (also present on the plasmid) was tested by polymerase chain reaction (PCR). A 2 µl aliquot of this suspension was added to 22 µl of PCR mixture (50 mM KCl, 10 mM Tris-HCl (pH: 8.3), 1.5 mM MgCl₂, 0.2 mM each deoxynucleotide triphosphate and 0.6 U of Taq DNA polymerase and 1 µl of primer mix 1 or 2 containing the primer at the concentration of 10 ng/µl each. All samples were amplified in a programmable Thermocycler (Eppendorf AG 2233, Hamburg, Germany) for the following cycling parameters: 95°C for 2 min to denature DNA, then 30 cycles of 30 s at 94°C, 30 s at 42°C to anneal the primers of the *IpaH* gene (Forward: 5'-CCTTTTCCGCGTTCCTTG A-3' and Reverse: 5'-CGGAATCCGGAGGTATTGC-3') (12) and 20 s at 72°C, and finally, one prolonged

extension at 72°C for 10 min. The PCR product bands of 620 base pairs were separated by electrophoresis through agarose gel 1.5% in 1X TBE buffer. DNA fragments visualized by ethidium bromide staining and photographed under UV light illumination.

Antibiotic susceptibility testing:

Isolates were tested for susceptibility to erythromycin (E, 10µg), cefalothin (CF, 30µg) tetracycline (TE, 30µg), ampicillin (AM, 10µg), ceftazidime (CAZ, 30µg), nalidixic acid (NA, 30µg), gentamicin (GM, 10µg), amoxicillin-clavulanic acid (AMC, 30µg), trimethoprim-sulfamethoxazole (SXT, 300µg), cefixime (CFM, 5µg), ceftriaxone (CRO, 30µg), chloramphenicol (C, 30µg), ampicillin-sulbactam (AS, 20 µg) and ciprofloxacin (CP, 5µg) by Kirby-Bauer disk diffusion method and the resistance break – point used were those recommended by the National Committee for Clinical Laboratory Standard (NCCLS)(13). Results were recorded as either sensitive or resistant. *Staphylococcus aureus* (ATCC 25923) American Type Culture Collection (ATCC), and *Escherichia coli* ATCC 25922 were used as quality control.

Statistical analysis:

All data were analyzed by SPSS software version 11.0 (SPSS Inc, Chicago, IL, USA). Comparative statistics were calculated using the two-tailed χ^2 test and Fisher's exact test, when appropriate. A p-value of ≤ 0.05 was considered to be significant.

RESULTS

From April 2004 to September 2005, the laboratory of RCGLD received and tested 1120 stool samples from patients with acute diarrhea. Among all enteropathogens, *Shigella* was commonest and isolated from 157(14.1%) samples. According to the serological tests, 88(56.1%) were identified as a *S. sonnei* and *S. flexneri*, *S. boydii* and *S. dysenteriae* were observed in 48(30.6%), 13(8.3%) and 8(5.1%), respectively.

Among cases, 66.3% were less than 5 years old whereas 11.5% were less than 1 year old. The prevalence of *Shigella* spp. isolated from the patients and their age distribution are shown in Table1. The isolation rate of *Shigella* spp. in spring, summer, fall and winter was 14.1 %, 51.6%, 19.8% and 14.7%, respectively. Of 88 *S. sonnei* and 46 *S. flexneri* isolates, 46(52%) and 22(25%) were isolated in the summer respectively (Figure1).

The antimicrobial resistant patterns of 14 different commonly used antibiotics were determined. *Shigella* isolates were determined by the Kirby-Bauer method. Result revealed that *Shigella* isolates were resistant to one or more agent 100 % while 91.7% were multidrug-resistant. *Shigella* strains showed high rates of resistance to tetracycline (95.5%) and sulfamethoxazol trimethoprim (91.7%). Also more than 90% of *Shigella* strains were susceptible to cefixime, ceftriaxone, ceftazidime, nalidixic acid, gentamicin, ciprofloxacin and ampicillin-sulbactam (Table2).

Table 1. Age distribution of *Shigella* spp. isolated from diarrheal patients in Iran

Pathogen	N (%)	0-12M	13-24M	25-36 M	37-48 M	49-60 M	>60M
S. sonnei	88(56.1*)	8(9.2)	12(13.6)	15(17)	18(20.4)	8(9.2)	27(30.6)
S.flexnery	48(30.6)	5(10.4)	3(6.3)	10(20.8)	5(10.4)	7(14.6)	18(37.5)
S. boydii	13(8.2)	0	0	6(46.1)	0	2(15.3)	5(38.6)
S. dysenteriae	8(5.1)	5(62.5)	0	0	0	0	3(37.5)

M: Month, * percentage

14 Antimicrobial resistance pattern of *Shigella* spp.




Figure 1. Number of *Shigella* spp. isolated from diarrheal patients in different seasons in Iran

Totally 85(96.5%) of *Shigella flexneri* strains were resistant to tetracycline and trimethoprim-sulfamethoxazole and 66(75.1%) to erythromycin.

All *S. sonnei* and *S. flexneri* strains were susceptible to chloramphenicol, ceftazidime and gentamicin. Meanwhile 97.4% of the isolates showed susceptibility to nalidixic acid and 99.3% to ampicillin-sulbactam. It was observed that 143(91%) strains were resistant to three or more antibiotic distributed into 25 distinct patterns. Of these, 6 strains were resistant to 6 antibiotics. The most frequent multidrug resistant pattern among *S. sonnei* was to erythromycin, tetracycline, sulfomethaxazol (21.6%) followed by erythromycin, tetracycline, ampicillin and sulfomethaxazol (18.18%).

Forty-eight strains of *Shigella flexneri* showed a high proportion of resistant strains to tetracycline (95.8%), sulfamethoxazol-trimethoprim (87.5%) and erythromycin (66.4%). Among *S. flexneri* strains, 8 were resistant to 6 antibiotics, however, we found 1 strain which was resistant to the following 7 antibiotics: erythromycin, cefixime, tetracycline, ampicillin, sulfamethoxazole-trimethoprim, ampicillin-sulbactam and chloramphenicol. The most frequent multidrug-resistant pattern among *S. flexneri* strains was the combined resistance to (erythromycin, tetracycline, ampicillin, sulfamethoxazol-trimethoprim, and ampicillin-sulbactam) which was found in 7(14.5%) isolates.

All the *Shigella boydii* strains were susceptible to ceftazidime, gentamicin, ceftriaxone, ciprofloxacin, and ampicillin-sulbactam while 74.9% of *Shigella boydii* strains were resistant to 3 or more antibiotics at the same time. Resistance to 6 antibiotics was also observed. Meanwhile *Shigella boydii* showed high susceptibility to chloramphenicol (92.3%), cefixime (61.4%) and nalidixic acid (84.6%). Despite, 84.6% were resistant to tetracycline (Table 2). All *Shigella dysenteriae* strains were resistant to tetracycline. Moreover *Shigella dysenteriae* were susceptible to ceftriaxone, ceftazidime, nalidixic acid, gentamicin, ciprofloxacin, chloramphenicol and ampicillin-sulbactam (100%).

Table 2. Antimicrobial resistance of *Shigella* spp. isolates from acute diarrhea in Iran

	E	CF	CFM	CRO	TE	SAM	AM	CAZ	SXT	NA	AMC	GM	C	CIP
<i>S. sonnei</i>	75	29.5	1.1	0	96.5	56.8	0	96.5	2.3	30.6	0	9	0	1.2
<i>S. flexneri</i>	66.4	8.3	0	0	95.8	47.9	0	87.5	0	54.1	4.2	47.9	0	0
<i>S. boydii</i>	84.6	38.4	0	0	84.6	38.4	0	76.9	15.4	61.5	0	7.6	0	0
<i>S. dysenteriae</i>	75	12.5	0	0	100	37.5	0	87.5	0	12.5	0	0	0	0

AM-ampicillin; SXT-trimethoprim-sulfamethoxazole; C-chloramphenicol; TE-tetracycline; CF-cephalothin; CRO-ceftriaxone; CIP-ciprofloxacin; GM-gentamicin; E-erythromycin; NA-nalidixic acid; CAZ-ceftazidime; SAM-ampicillin sulbactam; AMC-amoxicillin clavulanic acid; CFM-cefixime

DISCUSSION

Shigellosis is a world wide health concern especially in developing countries with poor sanitation, lack of personal hygiene and use of contaminated water supplies (14-16). Like many other developing countries, *Shigella* plays a significant role in the disease burden of Iran (17,18).

In this study, the frequency of dysentery among patients with acute diarrhea (9.6%) was more or as the same as other reports from developing countries (17,20,21).

In developing countries, *S. flexneri* is the predominant *Shigella* spp. recovered from patients with acute diarrhea and represents 50-70% of all *Shigella* isolates. Our results revealed the predominant prevalence of *Shigella sonnei* in children as well as in adults (17,18). Our result is in agreement with developed countries, even though, Iran is a developing country (22,23). *S. sonnei* is the predominant species and is more common in children than in adults. Like other countries the isolation rate of *Shigella* spp. was highest in summer (51.5%).

Multidrug-resistant patterns in bacterial pathogens are now common in developing countries such as Iran (24). Our results of antimicrobial susceptibility tests described relatively higher numbers of multidrug-resistant isolates compared with prior reports from Iran (17,25). It was clarified that 143(91%) strains were resistant to three or more antibiotics distributed into 25 distinct patterns. Interestingly, six strains were resistant to 6 different antibiotics while one strain was resistant even to 7 antibiotics. This could be explained by the fact that there are selective pressure causing the appearance and reemergence of specific strains (25). It has been reported that antimicrobial resistance gene can be readily transmitted between comensal enterobacteriaceae and enteropathogens in-vivo and in-vitro (26).

Shigella has been becoming resistant to most antibiotics commonly used in the treatment of diarrhea.

According to the susceptibility of the majority of *Shigella* spp. to cefixime, ciprofloxacin, ceftriaxone and nalidixic acid in this study, nalidixic acid is recommended as the drug of choice for shigellosis in both adults and children. Based on our findings, we conclude that *Shigella* spp. can be considered as an important etiological agent of diarrhea, with a high rate of drug resistance in the region.

Furthermore, our findings showed that third generation cephalosporins should be kept in reserve, only for the treatment of drug-resistant non-responsive cases of acute gastroenteritis. Notably, co-trimoxazole, tetracycline, and ampicillin had no reasonable role in the empirical treatment of gastroenteritis. These drugs could be replaced with other antibiotics such as quinolones.

Determining the prevalence rate of diarrheal pathogens should save the way for better control of the disease in the country. Continued vigilance of the safety of food, health education of food handlers, and close attention to hygiene and sanitary conditions can provide an effective barrier against the spread of shigellosis. The antimicrobial resistance may be as a result of inappropriate and wide use of different antibiotics to treat infection. The changing patterns of resistance to common antimicrobial agents in Iran indicates that designing a surveillance system for antimicrobial resistance and the introduction of integrated guidelines for the appropriate use of antibiotics are urgently needed.

ACKNOWLEDGEMENT

The authors are thankful to Nazanin Hosseinkhan, Navid Sahebekhtiari, Masumeh Azimi-rad, Kourosh Zolfagharian, Mastaneh Nochi and Hossein Dabiri for their technical support.

REFERENCES

1. Putnam SD, Riddle MS, Wierzbica TF, et al. Antimicrobial susceptibility trends among *Escherichia coli* and *Shigella* spp. isolated from rural Egyptian paediatric populations with diarrhoea between 1995 and 2000. *Clin Microbiol Infect* 2004;10(9):804-10.
2. Nguyen TV, Le PV, Le CH, et al. Antibiotic resistance in diarrheagenic *Escherichia coli* and *Shigella* strains isolated from children in Hanoi, Vietnam. *Antimicrob Agents Chemother* 2005;49(2):816-9.
3. Hirose K, Terajima J, Izumiya H, et al. Antimicrobial susceptibility of *Shigella sonnei* isolates in Japan and molecular analysis of *S. sonnei* isolates with reduced susceptibility to fluoroquinolones. *Antimicrob Agents Chemother* 2005;49(3):1203-5.
4. Nowroozi J, Hakemi vala M. Plasmid profile, antibiotic resistance, and phenotypic virulent strains of *S. flexneri*. *Iranian J Publ Health* 2006;35(4):43-48.
5. Hale TL. Review on genetic basis of virulence in *Shigella* species. *Microbiol Rev* 1991;55(2):206-24.
6. Naik DG. Prevalence and antimicrobial susceptibility patterns of *Shigella* species in Asmara, Eritrea, northeast Africa. *J Microbiol Immunol Infect* 2006;39(5):392-5.
7. Navia MM, Capitano L, Ruiz J, et al. Typing and characterization of mechanisms of resistance of *Shigella* spp. isolated from feces of children less than 5 years of age from Ifakara, Tanzania. *J Clin Microbiol* 1999;37(10):3113-7.
8. Taneja N, Mohan B, Khurana S, et al. Antimicrobial resistance in selected bacterial enteropathogens in north India. *Indian J Med Res* 2004;120(1):39-43.
9. Islam D, Lewis MD, Srijan A, et al. Establishment of a non-human primate *Campylobacter* disease model for the pre-clinical evaluation of *Campylobacter* vaccine formulations. *Gut* 2006;24(18):3762-71.
10. Bopps CA, Breener FW, Wells JG. *Escherichia*, *shigella* and *salmonella*. In: Murray PR, Baron EJ, Pfaller MA, editors. *Manual of clinical microbiology*. WB Saunders 1999;p:459-74.
11. Versalovic J, Koeuth TR, Lupski J. Distribution of repetitive DNA sequences in eubacteria and application to fingerprinting of bacterial genomes. *Nucleic Acids Res* 2004;19(24):6823-31.
12. Vu Dinh T, Sethabutr O, von Seidlein L, et al. Detection of *Shigella* by a PCR assay targeting the *ipaH* gene suggests increased prevalence of shigellosis in Nha Trang, Vietnam. *J Clin Microbiol* 2004;42(5):2031-35.
13. National Committee for Clinical Laboratory Standards, 1997. Performance Standards for Antimicrobial Disk Susceptibility Tests. Sixth edition. Wayne, PA: National Committee for Clinical Laboratory Standards. Approved Standard M2-A6.17: 1.
14. Wilson G, Easow JM, Mukhopadhyay C, et al. Isolation & antimicrobial susceptibility of *Shigella* from patients with acute gastroenteritis in western Nepal. *Indian J Med Res* 2006;123:145-50.
15. Young OJ, Sun YH, Kim SK, et al. Changes in patterns of antimicrobial susceptibility and integron carriage among *Shigella sonnei* isolates from Southwestern Korea during epidemic periods. *J Clin Microbiol* 2003;4:421-23.
16. Chu YW, Elizabeth T, Houang S, et al. Antimicrobial resistance in *Shigella flexneri* and *Shigella sonnei* in Hong Kong, 1986 to 1995. *Antimicrob Agents Chemother* 1998;42:440-43.
17. MoezArdalan K, Zali MR, Soltan Dallal MM, et al. Prevalence and pattern of antimicrobial resistance of *Shigella* species among patients with acute diarrhoea in Karaj, Tehran, Iran. *J Health Popul Nutr* 2003;21(2):96-102.
18. Rahbar M, Deldari M, Hajia M. Changing prevalence and antibiotic susceptibility patterns of different *Shigella* species in Tehran, Iran. *The Internet Journal of Microbiology* 2007;3:58-61.
19. Mehrabian S, Tohidpour M. Colicin Type biochemical type and drug resistance pattern of 154 strains of *Shigella sonnei* in Iran. *Pak J Med Sci* 2005;21:340-4.
20. Delappe N, Halloran F, Fanning S, et al. Antimicrobial resistance and genetic diversity of *shigella sonnei* isolates from western Ireland, an area of low incidence of infection. *J Clin Microbiol* 2003;41.
21. Fulla N, Prado V, Duran C, et al. Surveillance for antimicrobial resistance profiles among *Shigella* species isolated from a semirural community in the northern administrative area of Santiago, Chile. *Am J Trop Med Hyg* 2005;72(6):851-4.
22. Farshad S, Sheikhi R, Japoni A, et al. Characterization of *Shigella* strains in Iran by plasmid profile nalysis and PCR amplification of *ipa* genes. *J Clin Microbiol* 2006;44(8):2879-83.
23. Sumathi S, Nelson JM, Joyce K, et al. High prevalence of antimicrobial resistance among *Shigella* isolates in the United States tested by the National

Antimicrobial Resistance Monitoring System from 1999 to 2002. *Anti Microbiol Chemother* 2006;50:49–54.

24. Tjaniad P, Lesmana M, Subekti D, et al. Antimicrobial resistance of bacterial pathogens associated with diarrheal patients in Indonesia. *Am J Trop Med* 2003;68:666–70.

25. Farshad S, Sheikhi R, Japoni A, et al. Charecterization of *Shigella* strains by plasmid profile analysis and PCR amplification of *ipa* genes. *J Clin Microbiol* 2006;44:2879-83.

26. Pan TM. Bacillary dysentery in Taiwan 1995-1996. *Epidemiol Bull* 1997;13:151-61.